A Study of BMS-986218 or BMS-986218 Plus Nivolumab in Combination With Docetaxel in Participants With Metastatic Castration-resistant Prostate Cancer

NCT05169684 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

10

Enrollment

INDUSTRY

Sponsor class

Stopped Business objectives have changed

Conditions

Prostatic Neoplasms, Castration-Resistant

Interventions

BIOLOGICAL: BMS-986218
DRUG: Docetaxel
BIOLOGICAL: Nivolumab

Sponsor

Bristol-Myers Squibb